Regulatory Sanofi receives FDA approval for Tzield in paediatric diabetes Pharmaceutical Business ReviewThe approval expands the previous indication from those aged eight and above and was granted under a priority review process.RegulatoryMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaceutical Business Review The approval expands the previous indication from those aged eight and above and was granted under a priority review process. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: AbbVie opts for North Carolina to house $1.4bn manufacturing siteNext: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026